Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer (HOPS-R02)
jRCT1011180032Phase 2Completed
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC). Primary endpoint: Two year disease free survival. Started Mar 2018; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT1011180032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011180032.